

Seock-Ah Im

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4979401/seock-ah-im-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

311
papers

19,575
citations

55
h-index

137
g-index

342
ext. papers

26,195
ext. citations

7.7
avg, IF

6.48
L-index

#	Paper	IF	Citations
311	Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer.. <i>Journal of Korean Medical Science</i> , 2022 , 37, e34	4.7	
310	Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.. <i>Breast</i> , 2022 , 62, 52-60	3.6	1
309	The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology.. <i>BMC Medicine</i> , 2022 , 20, 72	11.4	1
308	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 556-567	59.2	29
307	Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. <i>Cancer Research</i> , 2022 , 82, P5-13-36-P5-13-36	10.1	
306	Abstract PD10-03: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O). <i>Cancer Research</i> , 2022 , 82, PD10-03-PD10-03	10.1	
305	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. <i>Cancer Research</i> , 2022 , 82, PD2-04-PD2-04	10.1	
304	Abstract P1-18-32: A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG BR19-15). <i>Cancer Research</i> , 2022 , 82, P1-18-32-P1-18-32	10.1	
303	Abstract PD15-08: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer. <i>Cancer Research</i> , 2022 , 82, PD15-08-PD15-08	10.1	0
302	Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. <i>Cancer Research</i> , 2022 , 82, GS1-02-GS1-02	10.1	1
301	Abstract P1-16-01: Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer: A randomized, open-label, multicenter, phase II trial (KCSG-BR15-17). <i>Cancer Research</i> , 2022 , 82, P1-16-01-P1-16-01	10.1	
300	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022 , 82, PD8-01-PD8-01	10.1	1
299	Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer. <i>Cancer Research</i> ,	10.1	0
298	Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestran) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease. <i>Cancer Research</i> , 2022 , 82, OT2-11-06-OT2-11-06	10.1	0
297	Abstract PD2-08: Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib. <i>Cancer Research</i> , 2022 , 82, PD2-08-PD2-08	10.1	0
296	Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-13-04-P2-13-04	10.1	1
295	Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03. <i>Cancer Research</i> , 2022 , 82, GS3-01-GS3-01	10.1	3

294	Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study. <i>Cancer Research</i> , 2022 , 82, P2-13-07-P2-13-07	10.1	2
293	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 1143-1154	59.2	25
292	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.. <i>BMC Medicine</i> , 2022 , 20, 105	11.4	2
291	The longitudinal effects of chronotype on chemotherapy-induced nausea and vomiting in patients with breast cancer receiving neoadjuvant chemotherapy.. <i>Journal of Psychosomatic Research</i> , 2022 , 157, 110804	4.1	0
290	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100896	2.2	3
289	338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study 2021 , 9, A364-A364		
288	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2021 , 53, 1096-1103	5.2	2
287	Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini's Mean Difference of Restricted Mean Survival Times. <i>Cancer Informatics</i> , 2021 , 20, 11769351211051675	2.4	1
286	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
285	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. <i>International Journal of Cancer</i> , 2021 ,	7.5	4
284	Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 77-89	4.4	0
283	Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. <i>Cancer Research and Treatment</i> , 2021 , 53, 1084-1095	5.2	1
282	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 499-511	21.7	68
281	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 573-584	13.4	65
280	Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2-advanced breast cancer: MONARCH 2 & 3 trials. <i>Cancer Science</i> , 2021 , 112, 2381-2392	6.9	4
279	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3113-3113	2.2	2
278	Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1000-1000	2.2	17
277	SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS1101-TPS1101	2.2	5

276	LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors. Results from the colorectal cancer cohort.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3564-3564	2.2	1
275	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. <i>British Journal of Cancer</i> , 2021 , 125, 679-686	8.7	7
274	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021 , 27, 713-718	12.9	8
273	Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , 2021 , 22, 85-97	21.7	24
272	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2021 , 39, 79-89	2.2	22
271	Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2021 , 53, 65-76	5.2	5
270	DNA Damage Repair Inhibitor for Breast Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1187, 159-179	3.6	
269	Development of a Novel Orthotopic Gastric Cancer Mouse Model. <i>Biological Procedures Online</i> , 2021 , 23, 1	8.3	3
268	Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 Activated T Cells. <i>Cancer Discovery</i> , 2021 , 11, 1100-1117	24.4	30
267	Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Journal of Breast Cancer</i> , 2021 , 24, 97-105	3	1
266	Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy. <i>Journal of Translational Medicine</i> , 2021 , 19, 7	8.5	
265	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021 , 23, 8	8.3	4
264	Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 377-386	4.4	4
263	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021 , 152, 68-77	7.5	5
262	Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL). <i>Cancer Research and Treatment</i> , 2021 , 53, 695-702	5.2	0
261	A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2021 ,	5.2	2
260	Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts. <i>Nature Communications</i> , 2021 , 12, 4840	17.4	3
259	Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2

258	Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase II Trial (KCSG-BR 15-10). <i>Cancers</i> , 2020 , 12,	6.6	4
257	Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1838-1849	6.3	5
256	Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. <i>Scientific Reports</i> , 2020 , 10, 8754-9	4.9	6
255	Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. <i>Scientific Reports</i> , 2020 , 10, 9930	4.9	17
254	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2020 , 21, 519-530	21.7	159
253	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. <i>Breast Cancer Research</i> , 2020 , 22, 27	8.3	7
252	TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. <i>Cancers</i> , 2020 , 12,	6.6	3
251	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 519-530	21.7	69
250	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1000-1000	2.2	92
249	Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1013-1013	2.2	18
248	A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1023-1023	2.2	12
247	SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1040-1040	2.2	2
246	BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3618-3618	2.2	4
245	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 500-500	2.2	14
244	Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS597-TPS597	2.2	2
243	Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer. <i>Journal of Breast Cancer</i> , 2020 , 23, 268-278	3	0
242	Thyroid Metastasis from Breast and Lung Cancer in Patients with Underlying Hashimoto's Thyroiditis. <i>International Journal of Thyroidology</i> , 2020 , 13, 175-180	0.2	
241	PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. <i>Cancers</i> , 2020 , 12,	6.6	49

240	Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2020 , 23, 182-193	3	4
239	Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant. <i>Cancer Research and Treatment</i> , 2020 , 52, 680-688	5.2	5
238	Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 1178-1187	5.2	6
237	Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020 , 71, 422-425	11.6	18
236	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 110-121	12.9	57
235	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 514-524	59.2	251
234	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 610-621	59.2	536
233	The effect of perceived social support on chemotherapy-related symptoms in patients with breast cancer: A prospective observational study. <i>Journal of Psychosomatic Research</i> , 2020 , 130, 109911	4.1	7
232	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1283-1295	21.7	62
231	Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 130	8.3	2
230	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , 2020 , 396, 1817-1828	40	306
229	HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 2243-2250	5.3	8
228	Homologous repair deficiency score for identifying breast cancers with defective DNA damage response. <i>Scientific Reports</i> , 2020 , 10, 12506	4.9	13
227	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. <i>Lancet Oncology, The</i> , 2020 , 21, 1155-1164	21.7	98
226	Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 743-753	4.4	1
225	Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 434-443	2.2	28
224	Morning chronotype is a protective factor against chemotherapy-induced hot flashes in premenopausal women with breast cancer. <i>Supportive Care in Cancer</i> , 2020 , 28, 1351-1358	3.9	4
223	Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, 98-107.e1	3	7

222	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019 , 120, 20-30	7.5	35
221	Targeted next-generation DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response. <i>International Journal of Radiation Biology</i> , 2019 , 95, 1640-1647	2.9	0
220	Prognostic effects of abnormal DNA damage response protein expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 117-127	4.4	4
219	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 5	7.8	176
218	Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. <i>Journal of Global Oncology</i> , 2019 , 5, 1-19	2.6	22
217	Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11). <i>Cancer Research</i> , 2019 , 79, 22-28	9.4	3
216	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 307-316	59.2	384
215	Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 453-460	4.4	5
214	Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. <i>International Journal of Cancer</i> , 2019 , 145, 1659-1678	7.5	10
213	Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 367-377	4.4	2
212	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients. <i>British Journal of Cancer</i> , 2019 , 121, 230-236	8.7	8
211	Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 549-559	4.4	20
210	Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2019 , 20, 1750-1759	21.7	56
209	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). <i>British Journal of Cancer</i> , 2019 , 121, 985-990	8.7	3
208	The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab. <i>Biomolecules</i> , 2019 , 9,	5.9	5
207	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1000-1000	2.2	56
206	In-depth gene expression analysis of premenopausal patients with HR+/HER2+ advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1018-1018	2.2	2
205	End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1020-1020	2.2	15

204	High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1030-1030	2.2	4
203	CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1031-1037	2.2	2
202	Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea. <i>Chinese Clinical Oncology</i> , 2019 , 8, 27	2.3	1
201	Amenorrhea and Menopause in Patients with Breast Cancer after Chemotherapy. <i>Journal of Breast Cancer</i> , 2019 , 22, 624-634	3	5
200	Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells. <i>Cancer Research and Treatment</i> , 2019 , 51, 451-463	5.2	9
199	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019 , 51, 211-222	5.2	5
198	Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. <i>Anti-Cancer Drugs</i> , 2019 , 30, 866-872	2.4	3
197	Prognostic Impact of Pregnancy in Korean Patients with Breast Cancer. <i>Oncologist</i> , 2019 , 24, e1268-e1275	5.7	5
196	Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. <i>Clinical Cancer Research</i> , 2018 , 24, 3348-3357	12.9	15
195	A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. <i>European Journal of Cancer</i> , 2018 , 93, 19-27	7.5	40
194	A First-in-Human Study of the New Oral Selective Estrogen Receptor Degradar AZD9496 for ER/HER2 Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 3510-3518	12.9	60
193	A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2018 , 18, 252	4.8	6
192	Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. <i>Nature Biomedical Engineering</i> , 2018 , 2, 239-253	19	12
191	Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer. <i>Journal of Psychosomatic Research</i> , 2018 , 108, 14-19	4.1	23
190	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 2804-2811	12.9	167
189	Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. <i>European Journal of Cancer</i> , 2018 , 101, 123-133	7.5	34
188	A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. <i>International Journal of Cancer</i> , 2018 , 143, 3240-3247	7.5	33
187	Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. <i>Cancer Letters</i> , 2018 , 430, 123-132	9.9	28

186	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. <i>Clinical Cancer Research</i> , 2018 , 24, 5860-5872	12.9	31
185	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1000-1000	2.2	12
184	Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1013-1013	2.2	5
183	EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician's choice (TPC) in OlympiAD.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1045-1045	2.2	3
182	Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1052-1052	2.2	8
181	Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 502-502	2.2	13
180	Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Poziotinib, pan-HER TKI.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13009-e13009	2.2	1
179	Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS1106-TPS1106	2.2	1
178	Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-	2.2	
177	Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1060-1060	2.2	1
176	Integrated F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 328-339	8.8	28
175	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2465-2472	2.2	435
174	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2018 , 36, 741-748	2.2	66
173	Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2018 , 50, 835-842	5.2	41
172	Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 2507-2518	6.1	10
171	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , 2018 , 104, 21-31	7.5	37
170	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2108-2121	59.2	1871
169	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 1926-1936	59.2	478

168	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018 , 103, 127-136	7.5	10
167	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018 , 103, 147-154	7.5	38
166	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 904-915	21.7	400
165	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 164-174	7.6	12
164	Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 254-262	7.6	40
163	AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 566-577	6.1	74
162	Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2017 , 25, 2241-2248	3.9	47
161	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. <i>New England Journal of Medicine</i> , 2017 , 377, 523-533	59.2	1405
160	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 904-916	21.7	330
159	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 329-341	4.4	31
158	Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. <i>European Journal of Cancer</i> , 2017 , 76, 205-215	7.5	11
157	Late chronotypes are associated with neoadjuvant chemotherapy-induced nausea and vomiting in women with breast cancer. <i>Chronobiology International</i> , 2017 , 34, 480-491	3.6	12
156	Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 365-371	1.9	
155	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1637-1651	21.7	174
154	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. <i>Cancer Treatment Reviews</i> , 2017 , 61, 53-60	14.4	31
153	Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics. <i>Korean Journal of Radiology</i> , 2017 , 18, 809-820	6.9	8
152	Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. <i>Oncotarget</i> , 2017 , 8, 2329-2341	3.3	39
151	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. <i>Oncotarget</i> , 2017 , 8, 63901-63910	3.3	26

150	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017 , 49, 1033-1043	5.2	10
149	Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. <i>Journal of Breast Cancer</i> , 2017 , 20, 347-355	3	8
148	Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study. <i>Journal of Breast Cancer</i> , 2017 , 20, 368-377	3	3
147	PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety	2.6	61
146	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1360-1372	21.7	263
145	Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2017 , 86, 385-393	7.5	18
144	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. <i>Oncologist</i> , 2017 , 22, 1028-1038	5.7	83
143	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDIAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. <i>European Journal of Cancer</i> , 2017 , 70, 146-155	7.5	88
142	Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. <i>International Journal of Cancer</i> , 2017 , 140, 109-119	7.5	35
141	Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1004-1004	2.2	6
140	Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) in PALOMA-3.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1050-1050	2.2	2
139	A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 509-509	2.2	6
138	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA4-LBA4	2.2	3
137	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA4-LBA4	2.2	25
136	Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. <i>Cancer Research and Treatment</i> , 2017 , 49, 350-357	5.2	14
135	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. <i>Cancer Research and Treatment</i> , 2017 , 49, 454-463	5.2	1
134	Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Cancer Research and Treatment</i> , 2017 , 49, 1153-1163	5.2	8
133	Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 416-416	2.2	

132	Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 460-460	2.2	
131	Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 454-454	2.2	
130	Serial monitoring of imatinib pharmacokinetics (PK) in perioperative imatinib treatment in patients (pts) with gastrointestinal stromal tumors (GISTs): Results from the multinational phase II trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 118-118	2.2	
129	A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteogastim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. <i>Supportive Care in Cancer</i> , 2016 , 24, 1709-17	3.9	15
128	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016 , 19, 421-430	7.6	10
127	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 597-606	7.6	21
126	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016 , 16, 515	4.8	10
125	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016 , 115, 1201-1205	8.7	12
124	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1925-1936	10.36	1278
123	Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival. <i>Radiology</i> , 2016 , 281, 392-400	20.5	61
122	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. <i>Nutrition and Cancer</i> , 2016 , 68, 750-5	2.8	
121	Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. <i>European Radiology</i> , 2016 , 26, 2771-8	8	26
120	Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016 , 115, 164-71	8.7	30
119	Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 233-41	4.4	7
118	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2016 , 17, 357-366	21.7	97
117	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 707-14	4.9	7
116	Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer. <i>Clinical and Experimental Metastasis</i> , 2016 , 33, 179-85	4.7	18
115	Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography. <i>European Radiology</i> , 2016 , 26, 2279-90	8	13

114	New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer. <i>Tumor Biology</i> , 2016 , 37, 11017-24	2.9	16
113	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , 2016 , 16, 22	4.8	43
112	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 1095-1103	4.1	26
111	SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. <i>Tumor Biology</i> , 2016 , 37, 4743-53	2.9	24
110	Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4041-4041	2.2	3
109	PEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 504-504	2.2	10
108	PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2-advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 507-507	2.2	58
107	Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy [results from Paloma-3.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 524-524	2.2	8
106	More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. <i>PLoS ONE</i> , 2016 , 11, e0145692	3.7	12
105	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. <i>PLoS ONE</i> , 2016 , 11, e0151406	3.7	13
104	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016 , 7, 76604-76612	3.3	77
103	The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. <i>Cancer Research and Treatment</i> , 2016 , 48, 171-9	5.2	46
102	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016 , 48, 1045-55	5.2	7
101	Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. <i>Cancer Research and Treatment</i> , 2016 , 48, 990-7	5.2	11
100	Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016 , 48, 1373-1381	5.2	6
99	Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2016 , 48, 499-507	5.2	
98	OOTR-N006: mTOR inhibition with everolimus in invasive breast cancer patients after pre-operative use of anthracycline and/or taxane-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e12507-e12507	2.2	2507
97	TTP or PFS as a surrogate endpoint in advanced hepatocellular carcinoma treated with systemic therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4075-4075	2.2	

96	Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23268-e23268	2.2	
95	Korean Cancer Patients' Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10067-10067	2.2	
94	Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features. <i>Oncotarget</i> , 2016 , 7, 81888-81898	3.3	1
93	Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016 , 7, 58007-58021	3.3	46
92	Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. <i>SpringerPlus</i> , 2016 , 5, 1033		5
91	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. <i>PLoS Medicine</i> , 2016 , 13, e1002136	11.6	25
90	Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 2016 , 19, 394-401	3	3
89	The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. <i>BMC Cancer</i> , 2016 , 16, 319	4.8	16
88	Longitudinal Association of Poor Sleep Quality With Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer. <i>Psychosomatic Medicine</i> , 2016 , 78, 959-965	3.7	14
87	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , 2016 , 17, 125-136	21.7	931
86	Overexpression of HIF1 β and CAXI predicts poor outcome in early-stage triple negative breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 469, 183-90	5.1	26
85	Src as a Therapeutic Target in Biliary Tract Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1515-24	6.1	8
84	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. <i>Lancet Oncology</i> , 2016 , 17, 791-800	21.7	408
83	Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1574-84	8.8	5
82	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2520-9	12.9	47
81	A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 1175-82	3.5	1
80	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 77-85	4.4	16
79	A Possible Association Between Thyroid Cancer and Breast Cancer. <i>Thyroid</i> , 2015 , 25, 1330-8	6.2	40

78	Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 3486-93	5.6	15
77	Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3858-65	2.2	202
76	Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015 , 467, 563-70	5.1	8
75	Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. <i>Clinical Epigenetics</i> , 2015 , 7, 63	7.7	15
74	Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. <i>BMC Cancer</i> , 2015 , 15, 690	4.8	7
73	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. <i>BMC Cancer</i> , 2015 , 15, 721	4.8	17
72	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2015 , 17, 33	8.3	110
71	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. <i>PLoS ONE</i> , 2015 , 10, e0139749	3.7	142
70	Nomogram for predicting breast conservation after neoadjuvant chemotherapy. <i>Cancer Research and Treatment</i> , 2015 , 47, 197-207	5.2	5
69	Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2015 , 18, 16-21 ³		35
68	Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. <i>Human Pathology</i> , 2015 , 46, 1027-35	3.7	26
67	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 1556-1568	21.7	63
66	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. <i>Oncologist</i> , 2015 , 20, 926-33	5.7	7
65	A histomorphologic predictive model for axillary lymph node metastasis in preoperative breast cancer core needle biopsy according to intrinsic subtypes. <i>Human Pathology</i> , 2015 , 46, 246-54	3.7	9
64	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. <i>American Journal of Cancer Research</i> , 2015 , 5, 3376-88	4.4	6
63	TGF- β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. <i>Cancer Research and Treatment</i> , 2015 , 47, 101-9	5.2	13
62	Efficacy and safety of regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: A multicenter study based on the management access program.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 175-175	2.2	
61	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. <i>European Journal of Cancer</i> , 2014 , 50, 698-705	7.5	23

60	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. <i>Oncologist</i> , 2014 , 19, 693-701	5.7	48
59	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2014 , 48, 13-25	4.8	15
58	Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. <i>Journal of Korean Medical Science</i> , 2014 , 29, 1094-101	4.7	14
57	Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging. <i>Radiology</i> , 2014 , 272, 385-96	20.5	65
56	Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker. <i>International Journal of Cancer</i> , 2014 , 134, 72-80	7.5	34
55	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3753-61	2.2	243
54	HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. <i>American Journal of Clinical Pathology</i> , 2014 , 142, 755-66	1.9	86
53	Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy. <i>Breast Cancer</i> , 2014 , 21, 387-93	3.4	12
52	A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2519-2519	2.2	6
51	Adenoid cystic carcinoma of the breast: a case series of six patients and literature review. <i>Cancer Research and Treatment</i> , 2014 , 46, 93-7	5.2	24
50	ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1038-1038	2.2	
49	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. <i>Anticancer Research</i> , 2014 , 34, 4275-80	2.3	6
48	Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy. <i>Breast Cancer</i> , 2013 , 20, 167-73	3.4	14
47	HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 109-15	3.5	13
46	Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1435-43	3.5	12
45	Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 1023-9	3.5	2
44	Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2242-9	3.1	12
43	RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 865-77	6.1	91

42	Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. <i>PLoS ONE</i> , 2013 , 8, e64271	3.7	61
41	Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1087-1087	2.2	1
40	Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2565-2565	2.2	1
39	Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAB), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3004-3004	2.2	3
38	Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4013-4013	2.2	23
37	A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(−) breast cancer who have not received any prior systemic anticancer treatment.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TP6112-TP6112	2.2	6
36	Clinical Implications of VEGF, TGF- β , and IL-1 β in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013 , 45, 325-33	5.2	34
35	Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 182-182	2.2	
34	Ki-67 level in hormone receptor positive breast cancer patients: A retrospective review of 9,061 Korean women.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 551-551	2.2	1
33	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15066-e15066	2.2	
32	Molecular characteristics and prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3550-3550	2.2	
31	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 303-13	4.8	52
30	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , 2012 , 13, 1225-33	21.7	389
29	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2012 , 13, 25-32	21.7	1438
28	Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 1133-40	4.4	12
27	Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 109-19	59.2	1752
26	Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 589-600	4.4	11
25	Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. <i>Anti-Cancer Drugs</i> , 2012 , 23, 288-97	2.4	14

24	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3076-3076	2.2	5
23	Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4124-4124	2.2	8
22	LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS649-TPS649	2.2	7
21	A Case of Disseminated Skin and Soft Tissue Infection due to Mycobacterium abscessus with Metastatic Breast Cancer. <i>Infection and Chemotherapy</i> , 2012 , 44, 201	3.9	1
20	Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3624-3624	2.2	
19	A multicenter phase II neoadjuvant trial of bevacizumab combined with docetaxel plus carboplatin in the treatment of triple-negative breast cancer: Korean Cancer Study Group (KCSG-BR 0905, NCT 01208480).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2542-2542	2.2	
18	Breast-conserving surgery after neoadjuvant chemotherapy for stage III breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e11532-e11532	2.2	
17	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. <i>Cancer Letters</i> , 2011 , 302, 155-65	9.9	39
16	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , 2011 , 13, R22	8.3	158
15	Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 465-77	7.3	20
14	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 1301-8	4.9	24
13	Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2011 , 11, 452	4.8	52
12	Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. <i>Diagnostic Molecular Pathology</i> , 2011 , 20, 94-100		24
11	Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. <i>Journal of Korean Medical Science</i> , 2009 , 24, 910-7	4.7	17
10	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 153-60	4.4	39
9	Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. <i>Annals of Surgical Oncology</i> , 2009 , 16, 1112-21	3.1	69
8	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , 2009 , 65, 80-4	5.9	105
7	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. <i>Cancer Letters</i> , 2008 , 272, 296-306	9.9	104

6	Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 589-95	2.8	22
5	Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer. <i>Journal of Korean Medical Science</i> , 2007 , 22 Suppl, S115-21	4.7	22
4	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. <i>BMC Cancer</i> , 2007 , 7, 203	4.8	111
3	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. <i>BMC Cancer</i> , 2007 , 7, 63	4.8	55
2	Alteration of Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Breast Cancer after Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 2007 , 10, 206	3	4
1	Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. <i>Tumori</i> , 2005 , 91, 513-21	1.7	16